GB2499666A - Mcl-1 inhibitors for the treatment of conditions associated with proliferative disorders - Google Patents
Mcl-1 inhibitors for the treatment of conditions associated with proliferative disorders Download PDFInfo
- Publication number
- GB2499666A GB2499666A GB1203350.2A GB201203350A GB2499666A GB 2499666 A GB2499666 A GB 2499666A GB 201203350 A GB201203350 A GB 201203350A GB 2499666 A GB2499666 A GB 2499666A
- Authority
- GB
- United Kingdom
- Prior art keywords
- group
- cancer
- nucleophile
- carbon
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 29
- 230000002062 proliferating effect Effects 0.000 title claims abstract description 17
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title claims description 43
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title claims description 43
- 239000003112 inhibitor Substances 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 143
- 239000012038 nucleophile Substances 0.000 claims abstract description 54
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 45
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 44
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 28
- 201000011510 cancer Diseases 0.000 claims abstract description 27
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000011593 sulfur Substances 0.000 claims abstract description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 23
- 125000004429 atom Chemical group 0.000 claims abstract description 22
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims abstract description 16
- 125000000101 thioether group Chemical group 0.000 claims abstract description 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 14
- 239000001301 oxygen Substances 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- 239000001257 hydrogen Substances 0.000 claims abstract description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 12
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 12
- 208000005623 Carcinogenesis Diseases 0.000 claims abstract description 11
- 230000036952 cancer formation Effects 0.000 claims abstract description 11
- 231100000504 carcinogenesis Toxicity 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 101
- 230000006907 apoptotic process Effects 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 27
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 230000001686 pro-survival effect Effects 0.000 claims description 15
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 230000035755 proliferation Effects 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 125000003277 amino group Chemical group 0.000 claims description 10
- 229940041181 antineoplastic drug Drugs 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 150000004820 halides Chemical class 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 239000003068 molecular probe Substances 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 3
- CVCLJVVBHYOXDC-AMTOVTBASA-N (2e)-2-[(5e)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C\2N=C3C=CC=CC3=C/2)N\C1=C\C=1NC(C)=CC=1C CVCLJVVBHYOXDC-AMTOVTBASA-N 0.000 claims description 2
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 208000009331 Experimental Sarcoma Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 201000004404 Neurofibroma Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000000516 mast-cell leukemia Diseases 0.000 claims description 2
- 201000008749 mast-cell sarcoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 229950004847 navitoclax Drugs 0.000 claims description 2
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 210000002229 urogenital system Anatomy 0.000 claims description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 208000035462 Biphenotypic Acute Leukemia Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000005508 null-cell leukemia Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000002511 pituitary cancer Diseases 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 description 88
- -1 ester Chemical class 0.000 description 65
- 239000000203 mixture Substances 0.000 description 26
- 230000001028 anti-proliverative effect Effects 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 19
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 16
- 230000001640 apoptogenic effect Effects 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 230000003013 cytotoxicity Effects 0.000 description 10
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 9
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 230000002424 anti-apoptotic effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000003211 malignant effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 7
- 230000032823 cell division Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000010287 polarization Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000012039 electrophile Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229930000755 gossypol Natural products 0.000 description 3
- 229950005277 gossypol Drugs 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 210000004882 non-tumor cell Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000051485 Bcl-2 family Human genes 0.000 description 2
- 108700038897 Bcl-2 family Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 201000011062 Li-Fraumeni syndrome Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000005035 acylthio group Chemical group 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 2
- 125000004647 alkyl sulfenyl group Chemical group 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000006319 alkynyl amino group Chemical group 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- IBAHLNWTOIHLKE-UHFFFAOYSA-N cyano cyanate Chemical group N#COC#N IBAHLNWTOIHLKE-UHFFFAOYSA-N 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 125000005291 haloalkenyloxy group Chemical group 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000000232 haloalkynyl group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000004476 heterocycloamino group Chemical group 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- 239000012948 isocyanate Chemical group 0.000 description 2
- 150000002513 isocyanates Chemical group 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004971 nitroalkyl group Chemical group 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 2
- 125000005499 phosphonyl group Chemical group 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010079882 Bax protein (53-86) Proteins 0.000 description 1
- 229940122035 Bcl-XL inhibitor Drugs 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000824799 Canis lupus dingo Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100536251 Mus musculus Tmem120a gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000006323 alkenyl amino group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229940076005 apoptosis modulator Drugs 0.000 description 1
- 230000009925 apoptotic mechanism Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007809 chemical reaction catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- LJJVZJSGXHJIPP-UHFFFAOYSA-N ethylpentyl Chemical group [CH2+]CCC[CH]C[CH2-] LJJVZJSGXHJIPP-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009701 normal cell proliferation Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 210000004287 null lymphocyte Anatomy 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to use of compounds represented by the general formula (I) : and pharmaceutically acceptable salts thereof, wherein n is an integer from 2 to 5; p is an integer from 0 to 4; R1 is independently selected from the group consisting of a hydroxl group, an alkoxy group, a thiol group, and a thioether group, wherein at least two of R1 are on the carbon-2 and carbon-5 positions of the phenyl group; R2 and R3 are independently a methylene group or a nucleophile; Z is an oxygen (O) atom or sulfur (S) atom; and T is hydrogen or an optionally substituted aliphatic group or optionally substituted aryl group; in the manufacture of a medicament for prevention and/or treatment and/or containment of a condition associated with a cell proliferative disorder. Particular conditions include tumorigenesis and cancer.
Description
NOVEL COMPOUNDS AND USES THEREOF Technical Field
5
The present invention generally relates to novel compounds, including phenolic analogues and derivatives thereof, which have anti-proliferative and/or apoptotic activities. The present invention also relates to the 10 use of such compounds in the treatment of conditions in which cells proliferate abnormally and/or show resistance to apoptosis.
Background
15
The rate of cell proliferation within a population of cells often depends on three main factors: i) the rate of cell division; ii) the proportion of cells within the population undergoing cell division; and iii) the 20 rate of cell loss from the population due to terminal differentiation or cell death. Physiological processes such as tissue development and homeostasis require a balance between cell proliferation and programmed cell death (apoptosis) . The role of apoptosis is to remove 25 harmful, damaged or unwanted cells. However, certain cells, such as tumor cells, may develop resistance to apoptosis by adaptations that protect the cells from cell death induced by their abnormal physiological state. In certain disease states, such as tumorigenesis and cancer, 30 it has been found that the tumor cells not only proliferate rapidly but may also show resistance to apoptosis, creating challenges in current cancer therapy.
1
The proteins of B-cell lymphoma 2 (Bcl-2) family are key regulators of apoptosis. The Bcl-2 family consists of several conserved sequence motif known as Bcl-2 homology (BH) domains. Bcl-2 family members are divided 5 into three groups based on the presence of BH domains. A first subfamily which includes Bcl-2, Bcl-xl and Mcl-1, contains BH1, BH2, BH3 and BH4 multi-domains and possesses pro-survival (anti-apoptotic) activity. A second subfamily which includes Bax and Bak, contains 10 multi-BH domains and possesses pro-apoptotic activity. A third subfamily which includes Bad, Bik and Bid, also exhibits pro-apoptotic activity and contains BH3 domains only.
Over expression of pro-survival proteins of the Bcl-15 2 family such as Bcl-xL and Mcl-1 is implicated in tumorigenesis. The BH1, BH2 and BH3 domains of pro-survival or anti-apoptotic proteins, e.g. Bcl-xL and Mcl-1, form a hydrophobic groove, which is the docking site for the BH3 domain of pro-apoptotic proteins. Binding of 20 the BH3 domain of Bak or Bax to the hydrophobic groove of the anti-apoptotic proteins can induce apoptotic effects. Hence, small molecules that inhibit the interaction of Bcl-xL/BH3 domain or Mcl-1/BH3 domain could potentially act as apoptosis modulators which will promote cell death 25 in cancer cells or enhance tumour sensitivity to chemotherapy or radiotherapy.
There is therefore a need for small molecules that are capable of inhibiting anti-apoptotic proteins such as Bcl-xL and Mcl-1. This is particularly important 30 considering that Mcl-1 has emerged as a major resistance factor in human chemoresistance of cancer cells. Small
2
molecules capable of inhibiting such anti-apoptotic proteins can lead to a better treatment option for cancer patients.
There is also a need for molecular probes and/or medicaments comprising such small molecules to be made available for studies and treatments involving conditions such as cancer or tumorigenesis in which cells proliferate abnormally and/or show resistance to apoptosis.
There is further a need for the small molecules to be easily obtained through a simple synthesis process.
Whilst a number of non-peptide small molecules have been developed and show activity as a Bcl-2 inhibitor, it may be useful to have small molecules that can inhibit both Bcl-2 and Mcl-1 and/or selectively inhibit any one of the anti-apoptotic proteins.
More importantly, there is a need for compounds that have anti-proliferative and/or apoptotic effects against cells that proliferate abnormally and/or show resistance to apoptosis, but which have no or low cytotoxicity to normal cells (e.g. non-cancerous or non-tumor cells), for use as anti-proliferative and/or apoptotic agents in studies and treatments involving conditions in which cells proliferate abnormally and/or show resistance to apoptosis.
Summary
According to a first aspect, there is provided use of a compound represented by the general formula (I):
3
n(R-i)
(I)
and pharmaceutically acceptable salts thereof, wherein
5 n is an integer from 2 to 5;
p is an integer from 0 to 4;
Ri is independently selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group, wherein at least two of Ri 10 are on the carbon-2 and carbon-5 positions of the phenyl group;
R2 and R3 are independently a methylene group or a nucleophile;
Z is an oxygen (0) atom or sulfur (S) atom; and 15 T is hydrogen or an optionally substituted aliphatic group or optionally substituted aryl group;
in the manufacture of a medicament for prevention and/or treatment and/or containment of a condition associated with a cell proliferative disorder. 20 According to a second aspect, there is provided use of a compound represented by the general formula (I):
4
and pharmaceutically acceptable salts thereof, wherein n is an integer from 2 to 5;
p is an integer from 0 to 4;
5 Ri is independently selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group, wherein at least two of Rx are on the carbon-2 and carbon-5 positions of the phenyl group;
10 R2 and R3 are independently a methylene group or a nucleophile;
Z is an oxygen (0) atom or sulfur (S) atom; and T is hydrogen or an optionally substituted aliphatic group or optionally substituted aryl group;
15 in the manufacture of a molecular probe.
According to a third aspect, there is provided use of a compound represented by the general formula (I):
Ra T
n(Ri) (I)
20 and pharmaceutically acceptable salts thereof, wherein
5
n is an integer from 2 to 5;
p is an integer from 0 to 4;
Ri is selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group, wherein at least two of Rx are on the carbon-2 and carbon-5 positions of the phenyl group;
R2 and R3 are independently a methylene group or a nucleophile;
Z is an oxygen (0) atom or sulfur (S) atom; and T is an optionally substituted aliphatic group having at least 9 carbon atoms;
in the manufacture of a medicament for the prevention and/or treatment of a condition associated with resistance to anti-cancer drugs.
According to a fourth aspect, there is provided a compound selected from the group consisting of:
o
O
O
O
O
6
F
O
O
N' H
OH
OH
HO'
HO'
HO
O
N
H
OH
OCH3
, and HO
According to a fifth aspect, there is provided a method of inducing apoptosis in a patient in need thereof comprising administering an effective amount of a compound represented by the general formula (I):
and pharmaceutically acceptable salts thereof, wherein n is an integer from 2 to 5;
p is an integer from 0 to 4;
Ri is independently selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group, wherein at least two of Ri n(Ri)
(I)
7
are on the carbon-2 and carbon-5 positions of the phenyl group;
R2 and R3 are independently a methylene group or a nucleophile;
5 Z is an oxygen (0) atom or sulfur (S) atom; and
T is hydrogen or an optionally substituted aliphatic group or optionally substituted aryl group.
Advantageously, the compounds of formula (I) and pharmaceutically acceptable salts thereof exhibit 10 inhibitory activity against anti-apoptotic proteins such as Bcl-xL and Mcl-1, and can therefore be used to selectively target such anti-apoptotic proteins in cells that over-express such proteins (e.g. cancerous or tumor cells). Advantageously, the compounds of formula (I) and 15 pharmaceutically acceptable salts thereof are not cytotoxic to, or have reduced cytotoxicity against normal ceils (e.g. non-cancerous or non-tumor cells).
Advantageously, the compounds of formula (I) and pharmaceutically acceptable salts thereof, can be 20 synthesized through a simple synthetic process.
According to a sixth aspect, there is provided a method of increasing sensitivity to chemotherapy in a patient in need thereof comprising administering an effective amount of an Mcl-1 inhibitor selected from a 25 compound represented by the general formula (I):
8
and pharmaceutically acceptable salts thereof, wherein n is an integer from 2 to 5;
p is an integer from 0 to 4;
5 Rx is selected from the group consisting of a hydroxyl group, an alkoxv group, a thiol group, and a thioether group, wherein at least two of Ri are on the carbon-2 and carbon-5 positions of the phenyl group;
R2 and R3 are independently a methylene . group or a 10 nucleophile;
Z is an oxygen (0) atom or sulfur (S) atom; and T is an optionally substituted aliphatic group having at least 9 carbon atoms.
Advantageously, the Mcl-1 inhibitors and 15 pharmaceutically acceptable salts thereof are capable of selectively causing apoptosis of cells that over-express the Mcl-1 protein, which has emerged as a major-resistance factor in human chemoresistance of cancer or tumor cells. Advantageously, the Mcl-1 inhibitors and 20 pharmaceutically acceptable salts thereof are also non-cytotoxic or have reduced cytotoxicity against normal cells (e.g. non-cancerous or non-tumor cells).
9
Definitions
The following are some definitions that may be helpful in understanding the description of the present 5 invention. These are intended as general definitions and should in no way limit the scope of the present invention to those terms alone, but are put forth for a better understanding of the following description.
Unless the context requires otherwise or
10 specifically stated to the contrary, integers, steps, or elements of the invention recited herein as singular integers, steps or elements clearly encompass both singular and plural forms of the recited integers, steps or elements.
15 Those skilled in the art will also appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications.
20 The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features.
25 The term "analogue" refers to a compound which comprises a chemically modified form of a specific compound or class thereof, and which maintains the chemical and/or biological activities that are characteristic of the specific compound and class. For
30 example, the term "analogue" as used herein may be used to refer to a chemically modified form of a compound of
10
formula (I) which maintains the cell anti-proliferative and/or apoptotic properties of a compound of formula (I).
The term "derivative" refers to any salt, solvate or prodrug, e.g. ester, of a compound of the invention, 5 which upon administration to a subject, is capable of providing (directly or indirectly) a compound of the invention, or an active metabolite or residue thereof. Preparation of such derivatives is routine to those skilled in the art without undue experimentation. 10 The term "active compound" in connection with the present invention is understood as meaning a compound as disclosed herein which is capable of causing a required therapeutic or non-therapeutic effect in a patient or subject, for example a cell anti-proliferative and/or 15 apoptotic effect.
The term "pharmaceutically acceptable salt" refers to those salts which retain the chemical and/or biological effectiveness and properties of the active compound, which are not otherwise undesirable. A thorough 20 discussion of pharmaceutically acceptable salts is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991) .
The term "optionally substituted" as used herein means the group to which this term refers may be 25 unsubstituted, or may be substituted with one or more groups independently selected from hydrogen, oxygen, sulfur, alkyl, alkenyl, alkynyl, thioalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, halo, carboxyl,
haloalkyl, haloalkynyl, hydroxyl, alkoxy, thioalkoxy, 30 alkenyloxy, haloalkoxy, haloalkenyloxy, nitro, amino, nitroalkyl, nitroalkenyl, nitroalkynyl,
11
nitroheterocyclyl, alkylamino, dialkylamino,
alkenylamine, alkynylamino, acyl, alkenoyl, alkynoyl, acylamino, diacylamino, acyloxy, alkylsulfonyloxy, heterocycloxy, heterocycloamino, haloheterocycloalkyl, 5 alkylsulfenyl, alkylcarbonyloxy, alkylthio, acylthio, phosphorus-containing groups such as phosphonyl and phosphinyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, cyano, cyanate, isocyanate, -C(0)NH(alkyl), and -C(0)N(alkyl)2.
10 The term "hydroxyl" as used herein refers to the functional group -OH.
The term "alkoxy" as used herein refers to straight chain or branched alkyloxy groups. Examples include methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, and 15 the like.
The term "thiol" means -SH.
The term "thioether" refers to ether groups wherein the oxygen is replaced with a sulfur. The thioether groups include but are not limited to -alkylene-S-alkyl, 20 -alkylene-S-aryl, -alkylene-S-arylalkyl, -alkylene-S-alkylaryl, -aryl-S-alkyl, -aryl-S-aryl, -aryl-S-alkylaryl, -aryl-S-arylalkyl, -arylalkyl-S-alkyl, arylalkyl-S-aryl, -arylalkyl-S-alkylaryl, -arylalkyl-S-arylalkyl, -alkylaryl-S-alkyl, -alkylaryl-S-aryl, 25 alkylaryl-S-alkylaryl, and -alkylaryl-S-arylalkyl. The thioether groups may be optionally substituted as described above.
The term "nucleophile" as used herein refers to a chemical moiety that has a reactive pair of electrons and 30 that participates in a chemical reaction by donating electrons, i.e., nucleophiles are electron donor
12
compounds. The nucleophile may be a halogen, nitrogen, sulfur or oxygen nucleophile. Exemplary nucleophiles include fluorides, cyanides, iodides, chlorides, bromides, acetates, enolates, primary amines, secondary 5 amines, amino, alkoxides, thiols, alkyl sulfides (such as mercaptans), hydroxides, azides, and hydrazines, among others.
The term "amino" as used herein refers to groups of the form -NRa or -NRaRb wherein Ra and Rb are independently 10 selected from the group including but not limited to hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy and optionally substituted aryl groups. For example, the term "amino" as used herein 15 may be used to refer to an -NH group at the R2 and/or R3 position of a compound of formula (I), or to an -NHCH3 group in the optionally substituted aliphatic group at the T position of a compound of formula (I).
The term "aliphatic" refers to a linear, branched, 20 or cyclic alkyl, alkenyl, or alkynyl group.
The term "alkyl" includes within its meaning straight chain or branched chain saturated aliphatic groups having from 1 to 10 carbon atoms, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. For example, the 25 term alkyl includes, but is not limited to, methyl, ethyl, 1-propyl, isopropyl, 1-butyl, 2-butyl, isobutyl, tert-butyl, amyl, 1, 2-dimethylpropyl, 1, 1-dimethylpropyl, pentyl, isopentyl, hexyl, 4-methylpentyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 2, 2-dimethylbutyl, 3,3-30 dimethylbutyl, 1, 2-dimethylbutyl, 1, 3-dimethylbutyl, 1,2,2-trimethylpropyl, 1, 1, 2-trimethylpropyl, 2-
13
ethylpentyl, 3-ethylpentyl, heptyl, 1-methylhexyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 4,4-dimethylpentyl, 1,2-dimethylpentyl, 1, 3-dimethylpentyi, 1,4-
dimethylpentyl, 1, 2, 3-trimethylbutyl, 1,1,2-
5 trimethylbutyl, 1, 1, 3-trimethylbutyl, 5-methylheptyl, 1-methylheptyl, octyl, nonyl, decyl, and the like.
The term "lower alkyl" refers to a straight or branched saturated hydrocarbon chain having 1, 2, 3, 4, 5, or 6 carbon atoms. This term is exemplified by groups 10 such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, n-hexyl, and the like.
The term "alkenyl" includes within its meaning straight or branched chain unsaturated aliphatic hydrocarbon groups having from 2 to 10 carbon atoms, 15 e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms and having at least one double bond, of either E, Zr cis or trans stereochemistry where applicable, anywhere in the alkyl chain. Examples of alkenyl groups include but are not limited to ethenyl, vinyl, allyl, 1-methylvinyl, 1-20 propenyl, 2-propenyl, 2-methyl-l-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2-butenyl, 3-butentyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1,3-pentadienyl, 2,4-pentadienyl, 1,4-pentadienyl, 3-methyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3-25 hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 2-
methylpentenyl, 1-heptenyl, 2-heptentyl, 3-heptenyl, 1-octenyl, 1-nonenyl, 1-decenyl, and the like.
The terra "lower alkenyl" refers to a straight or branched saturated hydrocarbon chain having 2, 3, 4, 5, 30 or 6 carbon atoms.
14
The term "alkynyl" as used herein includes within its meaning straight or branched chain unsaturated aliphatic hydrocarbon groups having from 2 to 10 carbon atoms and having at least one triple bond anywhere in the 5 carbon chain. Examples of alkynyl groups include but are not limited to ethynyl, 1-propynyl, 1-butynyl, 2-butynyl, l-methyl-2-butynyl, 3-methyl-l-butynyl, 1-pentynyl, 1-hexynyl, 1-methylpentynyl, 1-heptynyl, 2-heptynyl, 1-octynyl, 2-octynyl, 1-nonyl, 1-decynyl, and the like. 10 The term "lower alkynyl" refers to a straight or branched saturated hydrocarbon chain having 2, 3, 4, 5, or 6 carbon atoms.
The term "heteroatom" or variants such as "hetero-" as used herein refers to oxygen (0) , nitrogen (N) , 15 phosphorus (P) and sulfur (S).
The term "aryl" or variants such as "aromatic group" or "arylene" as used herein refers to single, polynuclear, conjugated or fused residues of aromatic hydrocarbons having from 6 to 10 carbon atoms. Exemplary 20 aryl groups include, but are not limited to phenyl, naphthyl, tetrahydronaphthyl, and the like.
The term "heteroaryl" and variants such as "heteroaromatic group" or "heteroarylene" as used herein, includes within its meaning single, polynuclear, 25 conjugated or fused aromatic moieties having 5 to 20 atoms wherein 1 to 6 atoms are heteroatoms selected from 0, N, NH and S. Examples of such groups include pyridyl, 2,2'-bipyridyl, phenanthrolinyl, quinolinyl, thiophenyl, indoyl, furanyl and pyrrolyl moieties and the like. 30 The term "cycloalkyl" as used herein refers to cyclic saturated aliphatic groups and includes within its
15
meaning monocyclic, bicyclic, polycyclic or fused polycyclic hydrocarbon moieties having from 3 to 10 carbon atoms, e.g., 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. Examples of cycloalkyl groups include but are not 5 limited to cyclopropyl, 2-methylcyclopropyl, cyclobutyl, cyclopentyl, 2-methylcyclopentyl, 3-methylcyclopentyl, cyclohexyl, and the like.
The term "halide" or variants such as "halogen" or "halo" as used herein refers to fluoride, chloride, 10 bromide and iodide.
The present invention includes within its scope all isomeric forms of the compounds disclosed herein, including all diastereomeric isomers, racemates and enantiomers. Thus, compounds of formula (I) and 15 derivatives thereof should be understood to include, for example, E, Z, cis, trans, (R), (S), (L), (D), (+), and/or (-) forms of the compounds, as appropriate in each case.
The term "normal" when used in the context of 20 "normal cell," is meant to refer to a cell exhibiting a normal or unaltered cellular and/or physiological state, for example a cell having normal rate of cell division or cellular differentiation. A "normal" cell, for example, includes one that does not exhibit a malignant phenotype, 25 such as a non-cancerous or non-tumor ceil.
The term "abnormal" when used with reference to a cell or cells, includes but is not limited to, a cell or cells whose growth is independent of normal regulatory mechanisms. Such "abnormal" cells exhibit an increase 30 in the rate of cell division or an alteration in cellular differentiation relative to "normal cells." Altered
16
cellular differentiation can be evidenced, for example, by altered cell surface protein expression. Such
"abnormal" cells may also proliferate uncontrollably as a result of loss of normal cell cycle checkpoints, loss of 5 contact inhibition, etc. An "abnormal" cell includes one that exhibit a malignant phenotype, such as a cancerous or tumor cell.
The term "targeted cell" refers to a cell where a reduction in its proliferation is desired. One or more 10 targeted cells may be present. Thus, there may be a population of targeted cells. Reduction in proliferation of a targeted cell or population of targeted cells includes reduction in the rate of proliferation and/or reduction in the amount of proliferation. Thus, for 15 example, the rate of cell division may be reduced and/or the total amount of cell division may be reduced.
The term "proliferation", or grammatical variants thereof, when used in relation to a cell or cells, includes any process (such as any asexual process) 20 whereby the targeted cell gives rise to one or more further cells. Thus, proliferation includes the generation of new cells by processes such as cell division.
The terms "cell proliferation", "proliferative 25 condition", "proliferative disorder" and "proliferative disease" refer to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether in vitro, in vivo or ex vivo. Exemplary 30 proliferative conditions include, but are not limited to, pre-malignant and malignant cellular proliferation, such
17
as malignant neoplasms, tumors (e.g. solid tumors), cancers, leukemia, and the like.
The term "anti-proliferative" or "anti-proliferation" as used herein refers to prevention, 5 retardation or inhibition of the growth or multiplication of a single cell or a colony of cells. Several mechanisms exist to induce an "anti-proliferative" or "anti-proliferation" effect. Exemplary mechanisms include, but are not limited to, interfering with the 10 mitotic process for somatic cell proliferation or inducing cytotoxicity and/or apoptosis in damaged or unwanted cells.
The term "anti-proliferative agent" as used herein refers to a compound which treats a cell proliferative 15 condition (i.e. a compound which is useful in the treatment of a cell proliferative condition). Antiproliferative agents disclosed herein may be apoptotic agents, and have application in the treatment of cancer, and so the present invention further provides anti-cancer 20 agents.
The term "anti-cancer agent" refers to a compound which treats a cancer (i.e. a compound which is useful in the treatment of a cancer). The anti-cancer effect may arise through one or more mechanisms including, but are 25 not limited to, the regulation of cell proliferation, the inhibition of metastasis (the spread of a tumor from its origin), the inhibition of angiogenesis (the formation of new blood vessels), the inhibition of invasion (the spread of tumor cells into neighbouring normal 30 structures), or the promotion of apoptosis.
18
The term "treatment" includes any and all uses which remedy a disease state or symptoms, prevent the establishment of disease, or otherwise prevent, hinder, retard, or reverse the progression of disease or other 5 undesirable symptoms in any way whatsoever. Hence, "treatment" includes prophylactic and therapeutic treatment.
The term "patient" or "subject" refers to patients or subjects of human or other mammal and includes any 10 individual it is desired to examine or treat using the active compounds and methods disclosed herein. However, it will be understood that "patient" or "subject" does not imply that symptoms are present. Suitable mammals that fall within the scope of the invention include, but 15 are not restricted to, primates, livestock animals (eg.
sheep, cows, horses, donkeys, pigs), laboratory test animals (e.g. rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g. cats, dogs) and captive wild animals (e.g. foxes, deer, dingoes). 20 "Mammal" refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, and pet companion animals such as a household pet and other domesticated animal such as, but not limited to, cattle, sheep, ferrets, swine, horses, poultry, 25 rabbits, goats, dogs, cats and the like. Preferred companion animals are dogs and cats. Preferably, the mammal is human.
The term "administering" and variations of that term including "administer" and "administration", includes 30 contacting, applying, delivering or providing a compound
19
or composition of the invention to an organism, or a surface by any appropriate means.
The term "effective amount" when used in relation to an anti-proliferative or an apoptotic agent, refers to an 5 amount sufficient to effect the desired antiproliferative or apoptotic benefit. Similarly, the terms "therapeutically effective amount" and "pharmaceutically effective amount" include within their meanings a sufficient but non-toxic amount of a compound or 10 composition of the invention to provide the desired therapeutic effect. The exact amount required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, 15 the particular agent being administered, the mode of administration, and so forth. Thus, it is not possible to specify an exact "effective amount". However, for any given case, an appropriate "effective amount" may be determined by one of ordinary skill in the art using only 20 routine experimentation.
The term "dosage unit form" as used herein refers to physically discrete units suited as unitary dosages for the individual to be treated; each unit containing a predetermined quantity of compound(s) is calculated to 25 produce the desired therapeutic effect in association with the required pharmaceutical carrier. The compound(s) may be formulated for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in an acceptable 30 dosage unit. In the case of compositions containing supplementary active ingredients, the dosages are
20
determined by reference to the usual dose and manner of administration of the ingredients.
Unless specified otherwise, the terms "comprising" and "comprise", and grammatical variants thereof, are 5 intended to represent "open" or "inclusive" language such that they include recited elements but also permit inclusion of additional, unrecited elements.
As used herein, the term "about", in the context of concentrations of components of the formulations, 10 typically means +/- 5% of the stated value, more typically +/- 4% of the stated value, more typically +/-3% of the stated value, more typically, + /- 2% of the stated value, even more typically +/- 1% of the stated value, and even more typically +/- 0.5% of the stated 15 value.
Throughout this disclosure, certain embodiments may be disclosed in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an 20 inflexible limitation on the scope of the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a 25 range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies 30 regardless of the breadth of the range.
21
Certain embodiments may also be described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the disclosure. This 5 includes the generic description of the embodiments with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.
10 Detailed Disclosure of Embodiments
Exemplary, non-limiting embodiments of the active compounds having cell anti-proliferative and/or apoptotic activities will now be disclosed.
15 The inventors have found that the active compounds disclosed herein exhibit potent cell anti-proliferative and/or apoptotic activities. Accordingly, the active compounds disclosed herein can be used as cell antiproliferative and/or apoptotic agents in medicaments to 20 treat or prevent any conditions in which cells proliferate abnormally and/or show resistance to apoptosis. The active compounds disclosed herein can also be used as molecular probes to delineate the biological pathways and mechanisms in
25 carcinogenesis/tumorigenesis and chemoresistance.
Further, the active compounds disclosed herein can be used in the manufacture of a medicament for the prevention and/or treatment of a condition associated with resistance to anti-cancer drugs, for example 30 resistance to anti-cancer drugs such as ABT-737, GX15-070, ABT-263 and/or AT-101, and the like.
22
The Active Coxaponnds
The active compounds may be represented by a compound having the general formula (I):
n(Ri)
R* T
(i)
and pharmaceutically acceptable salts thereof, wherein n is an integer from 2 to 5;
p is an integer from 0 to 4;
10 Ri is independently selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group, wherein at least two of Ri are on the carbon-2 and carbon-5 positions of the phenyl group;
15 R2 and R3 are independently a methylene group or a nucleophile;
Z is an oxygen (0) atom or sulfur (S) atom; and T is hydrogen or an optionally substituted aliphatic group or optionally substituted aryl group.
20 In one embodiment, Z is an oxygen (0) atom.
In another embodiment, Z is a sulfur (S) atom.
In one embodiment, n is 2.
In a preferred embodiment, n is 2 and each of Ri is -OH. Preferably, in embodiments where n is 2 and each of
23
Ri is -OH, one of Ri is on the carbon-2 position and the other Ri is on the carbon-5 position of the phenyl group.
In one embodiment, n is 2 and one of Ri is -OH and the other of Ri is -OCH3.
5 Advantageously, in embodiments where n is 2 and each of Rx is -OH on the carbon-2 and carbon-5 position, respectively, the compounds of formula (I) exhibit high anti-proliferative and/or apoptotic activity, and reduced or no cytotoxicity.
10 In one embodiment, Z is an oxygen (0) atom, n is 2,
and each of Rx is -OH.
In one embodiment, Z is a sulfur (S) atom, n is 2, and each of Ri is -OH.
p can be 0, 1, 2, 3 or 4.
15 In one embodiment, p is 0.
In one embodiment, Rx is hydroxyl.
In one embodiment, Rx is OU wherein U is hydrogen or an alkyl group having from 1 to 6 carbon atoms.
In another embodiment, Rx is ZxTx, wherein Zx is a 20 sulfur (S) atom or oxygen (O) atom and Tx is a lower alkyl group. The lower alkyl may have from 1 to 6 carbon atoms.
In yet another embodiment, Rx is independently selected from the group consisting of -OH, -OCH3, 25 OCH2CH3, -OCH2CH2CH3, -OCH2CH2CH2CH3, -OCH2CH2CH2CH2CH3, -OCH2CH2CH2CH2CH2CH3, -SH, -SCH3, -SCH2CH3, -SCH2CH2CH3, -SCH2CH2CH2CH3, -SCH2CH2CH2CH2CH3 and -SCH2CH2CH2CH2CH2CH3.
In some embodiments where n is 2, 3, 4 or 5, all the Rx groups are the same. For example, where n is 2, both 30 Rx groups may be -OH, both R;l groups may be -OCH3, both Rx groups may be OCH2CH3, both Rx groups may be -OCH2CH2CH3,
24
both Ri groups may be -OCH2CH2CH2CH3, both Ri groups may be -OCH2CH2CH2CH2CH3, both Ri groups may be OCH2CH2CH2CH2CH2CH3, both Rx groups may be -SH, both Rx groups may be -SCH3, both Rx groups may be -SCH2CH3, both Rx groups may be -SCH2CH2CH3, both Rx groups may be SCH2CH2CH2CH3, both Rx groups may be -SCH2CH2CH2CH2CH3, or both Rx groups may be -SCH2CH2CH2CH2CH2CH3.
In other embodiments where n is 2, 3, 4 or 5, each Rx group is different. For example, where n is 2, one Rx group may be -OH and the other Rx group may be OCH2CH2CH3, or where n is 3, two Rx groups may be -OH and the third Rx group may be -OCH3 or the first Rx group may be -OH, the second Rx group may be -OCH3 and the third Rx group may be -OCH2CH2CH3.
In one embodiment, T is an aliphatic group with 1 to 20 carbons. For example, T may be an aliphatic group with 1 to 19 carbons, 1 to 18 carbons, 1 to 17 carbons, 1 to 16 carbons, 1 to 15 carbons, 1 to 14 carbons, 1 to 13 carbons, 1 to 12 carbons, 1 to 11 carbons, 1 to 10 carbons, 1 to 9 carbons, 1 to 8 carbons, 1 to 7 carbons,
1 to 6
carbons,
1
to 5 carbons
, 1
to
4 carbons f
1 to
3
carbons
, 1
to
2
carbons,
2
to
20
carbons,
3
to
20
carbons
, 4
to
2 0
carbons,
5
to
20
carbons,
6
to
20
carbons
, 7
to
20
carbons,
8
to
20
carbons,
9
to
20
carbons
, 10
to
20
carbons,
11
to
20
carbons,
12
to
20
carbons
, 13
to
20
carbons,
14
to
20
carbons,
15
to
20
carbons
, 16
to
20
carbons,
17
to
20
carbons,
18
to
20
carbons, or 19 to 20 carbons.
In one embodiment, T is an aliphatic group with 1 to 8 carbons. In one embodiment, T is an aliphatic group with 1, 2, 3, 4, 5, 6, 7 or 8 carbons.
25
In one embodiment, T is an aliphatic group with 6 carbons.
In one embodiment, T is an aliphatic group with 8 carbons.
5 In another embodiment, T is an aliphatic group with at least 9 carbons. In one embodiment, T is an aliphatic group with 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbons.
In one embodiment, T is an aliphatic group with 9 10 carbons.
In one embodiment, T is an aliphatic group with 10 carbons.
In one embodiment, the aliphatic group of T is an alkyl. In one embodiment, the alkyl is a lower alkyl. 15 The alkyl may be straight chain alkyl or a branched chain alkyl. Preferably, the alkyl is a straight chain alkyl. The alkyl may be -CH3, -CH2CH3, -CH5.CH5.CH3, -CH5.CH5.CH5.CH3, -CH2CH2CH2CH2CH3, -CH2CH2CH2CH2CH2CH3, -CH2CH2CH2CH2CH2CH2CH3, -CH2CH2CH2CH2CH2CH2CH2CH3, -CH2CH2CH2CH2CH2CH2CH2CH2CH3,
20 CH2CH2CH2CH2CH2CH2CH2CH2CH2CH3 or -CH(CH3)2.
In another embodiment, the aliphatic group of T is an aliphatic group containing at least one unsaturated alkenyl or alkynyl group, preferably lower alkenyl or lower alkynyl groups. Suitable alkenyl groups include -25 CHCH2, -CH2CHCH2, -CHCHCH3, and -CHCHCH3, while suitable alkynyl groups include -CCCH3, -CH2CCH, -CH2CH2CCH, -CH2CH2CH2CCH, -CH2CH2CH2CH2CCH, and -CH2CCCH3.
The aliphatic group of T may be optionally substituted as described above.
30 In one embodiment, T is an aliphatic group substituted with one or more heteroatom groups. Suitable
26
heteroatom groups include, without limitation, oxygen (0), sulfur (S), and nitrogen (N) and phosphorous (P).
In another embodiment, T is an aryl group, heteroaryl group or cycloalkyl group, each optionally 5 substituted with one or more groups selected from hydrogen, oxygen, sulfur, alkyl, alkenyl, alkynyl, thioalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, halo, carboxyl, haloalkyl, haloalkynyl, hydroxyl, alkoxy, thioalkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, 10 nitro, amino, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroheterocyclyl, alkylamino, dialkylamino,
alkenylamino, alkynylamino, acyl, alkenoyl, alkynoyl, acylamino, diacylamino, acyloxy, alkylsulfonyloxy, heterocycloxy, heterocycloamino, haloheterocycloalkyl, 15 alkylsulfenyl, alkylcarbonyloxy, alkylthio, acylthio, phosphonyl, phosphinyl, aryl, heteroaryl, alkylaryl, alkylheteroaryl, cyano, cyanate, isocyanate, C(0)NH(alkyl), and -C(0)N(alkyl).
In one embodiment, T is optionally substituted with 20 a benzodioxole. In one embodiment, the benzodioxole is a 1,3-benzodioxole.
In one embodiment, both R2 and R3 are methylene groups. In another embodiment, one of R2 and R3 is a methylene group and the other is a nucleophile. In yet 2 5 another embodiment, both R2 and R3 are nucleophiles.
In one embodiment, R2 is a methylene group.
In one embodiment, R3 is a nucleophile.
In one embodiment, R2 is a methylene group and R3 is a nucleophile.
30 In one embodiment, the nucleophile of R2 and/or R3
is selected from the group consisting of a halide, a
27
nitrogen nucleophile, a sulfur nucleophile and an oxygen nucleophile.
Suitable halides include, but are not limited to, fluoride, chloride, bromide and iodide, and the like.
5 Suitable nitrogen nucleophiles include, but are not limited to, amino groups (e.g. primary amino groups, secondary amino groups and tertiary amino groups), and azides (e.g. metal azides of Li, Na or K), and the like.
Suitable sulfur nucleophiles include thiols and 10 alkyl sulfides, and the like.
Suitable oxygen nucleophiles include acetates, enolates, alkoxides, and hydroxides, and the like.
The halide, nitrogen nucleophile, sulfur nucleophile and oxygen nucleophile may be optionally substituted as 15 described above.
In one embodiment of the compounds described herein, the nucleophile of R2 and/or R3 is a nitrogen nucleophile.
In one embodiment, the nitrogen nucleophile is an 20 amino group. The amino group may be a NH group, a NHV group or a NVV' group where V and V' are each independently selected from the group consisting of a Ci~ C4 lower alkyl, a phenyl, and an alkoxy group.
In one embodiment, the compound has the formula (I-
25 A) :
o
In another embodiment, the compound has the formula (I-B):
28
N' H
OH
HO
In another embodiment, the compound has the formula (I-C):
O
HO
In another embodiment, the compound has the formula
(I-D)
10
HO
In another embodiment, the compound has the formula
(I-E):
O
HO
N H
OH
N
In another embodiment, the compound has the formula (I-F):
O
Q
>
o
HO
In another embodiment, the compound has the formula 15 (I-G) :
29
o
HO
In another embodiment, the compound has the formula
I-H)
O
In another embodiment, the compound has the formula I-I) :
O
N H
OH
HO
In another embodiment, the compound has the formula
I-J) :
O
HO
N H
OH
In another embodiment, the compound has the formula
I-K)
O
HO
N
H
OH "OCHq
30
10
15
20
In another embodiment, the compound has the formula (I-L):
Since the disclosed active compounds may have asymmetric carbon centers, they can be present in the form of racemate, diastereomers or mixtures thereof. Therefore, the present invention also includes all these isomers and their mixtures.
Synthesis of Active Compounds
The disclosed active compounds having the general formula (I) may be prepared by a process as described below.
Generally, the active compounds are synthesized via nucleophilic substitution reactions. A nucleophile and a second reactant (an electrophile) are mixed in an anhydrous solvent, and stirred at room temperature to produce the active compounds. The active compounds are extracted with an organic solvent, and the resulting organic extracts are concentrated under reduced pressure to give a crude product.
The nucleophile in this instance may be an amine having a formula (la), or a hydrochloride or hydrobromide salt thereof having a formula (la') as shown below:
H
31
V""2
R
, .NHoHX
Vn
R
(la)
(la' )
where R is selected from the group consisting of aliphatic alkyls, substituted phenyls, unsubstituted phenyls and heterocycles, n is 1 or 2, and X is CI or Br.
Alternatively, the nucleophile is a straight chain amine having a formula (la"):
where n is 1 or 3.
The electrophile is a lactone.
The nucleophile and the electrophile are typically used in a stoichiometric ratio, but the excess of one component or the other may be advantageous.
The anhydrous solvent is N,N-dimethylformamide (DMF), dichloromethane or tetrahydrofuran.
Where the nucleophile used is a hydrochloride or hydrobromide salt of an amine having a formula (la'), N,N-diisopropylethylamine (DIPEA) can be added to liberate the amine group.
The reaction catalyst added is 2-hydroxypyridine.
Typically, the mixture is stirred at room temperature for 6 to 24 h before being extracted with an organic solvent such as dichloromethane. The organic extract is concentrated under reduced pressure to give a crude active compound, which is then purified using silica gel column chromatography or preparative high performance liquid chromatography.
(la")
32
Active Compound Salts
In some forms, it may be desirable to formulate the 5 active compounds in pharmaceutically acceptable salt form, generally to improve the solubility and bioavailability and to provide an active compound that may be capable of being assimilated readily. Preferably, the pharmaceutically acceptable salts are suitable for 10 use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
The active compounds may form pharmaceutically 15 acceptable salts with both organic and inorganic acids. Suitable physiologically tolerated acids for salt formation may be organic and inorganic acids, such as hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, 20 ascorbic, maleic, methanesulfonic, isethionic, lactic, gluconic, glucuronic, sulfamic, benzoic, tartaric, pamoic, and the like.
The salts may be prepared by contacting a free base form with an equivalent amount of the desired acid in the 25 conventional manner. The free base forms may be regenerated by treating the salt form with a base. For example, dilute aqueous base solutions may be utilized. Dilute aqueous sodium hydroxide, potassium carbonate, ammonia, and sodium bicarbonate solutions may be suitable 30 for this purpose.
33
The free base forms may differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvent. Otherwise, the salts may be equivalent to their respective free base forms for 5 purposes of the invention.
The active compounds may exist in unsolvated as well as solvated forms, including hydrated forms. Such salt forms of the active compound may be provided or mixed prior to use with a physiologically acceptable solvent 10 such as water or elhanol.
Therapeutic Uses of Active Compounds
(a) Use as Apoptotic Agents
15
It has been found that the active compounds of general formula (I) have potent apoptotic activity and are able to induce cell apoptosis by inhibiting the functions of pro-survival proteins such as Bcl-xL and 20 Mcl-1. Hence, the disclosed active compounds have the potential to be developed into useful therapeutic agents for treatment of conditions requiring apoptosis or in which cells show resistance to apoptosis. Accordingly, the disclosed active compounds may be envisaged as being 25 useful for use as apoptotic agents in the treatment of conditions such as tumorigenesis and/or cancer.
(b) Use as Anti-proliferative Agents
30 The active compounds of general formula (I) are capable of inducing apoptosis in targeted cells.
34
Accordingly, the active compounds can be used to treat diseases and conditions associated with the undesired proliferation of targeted cells.
Additionally, the active compounds may find utility 5 in vitro. For instance, the compounds may find utility in controlling the growth of undesired cells, such as cancer cell lines. The compounds may find utility as a research tool, for instance in studying the mechanisms of apoptosis.
10 The active compounds of the invention may be used to reduce the proliferation of a targeted cell.
In one embodiment the targeted cell, or one or more of its progeny, dies as a result of exposure of the targeted cell to an active compound of the invention. In 15 one embodiment, the targeted cell, or one or more of its progeny, undergoes apoptosis.
A "reduction in the proliferation" of a targeted cell (and similar expressions) includes where there is a reduction in the number of, or rate of, generation of 20 progeny cells arising from the targeted cell (e.g.
whether as daughter, grand-daughter, great-grand-daughter cells etc.).
As discussed herein, the active compounds of the invention are envisaged as being useful in the treatment 25 of patients suffering from a condition where proliferation of abnormal or unwanted cells occur, for example where the cells are resistant to apoptosis. Suitably, the anti-proliferative effect of the active compounds disclosed herein is specific for the targeted 30 cells, that is the targeted cells are more sensitive to the anti-proliferative effect of the compounds of the
35
invention than the non-targeted cells (e.g. "wild-type" cells which undergo normal cell proliferation and/or have normal regulation of apoptotic processes). Hence, where the patient is a cancer patient, the cancerous cells are affected to a greater extent than the patient's noncancerous cells. The targeted cell may be a eukaryotic cell which may be an animal cell.
In one embodiment, the targeted cell has aberrant expression of Bcl-xL and/or Mcl-1 and/or is resistant to apoptosis. For example, Bcl-xL and/or Mcl-1 is overexpressed in endometrial, gastric and colorectal carcinomas, carcinomas of the breast, colon, lung, bladder, ovary and vulva, sarcomas, lymphomas (AML, NHL), and Li-Fraumeni syndrome. In one embodiment, the targeted cell is a cancer cell.
(c) Use as Anti-cancer Agents
The active compounds of general formula (I) are capable of irreversibly arresting mitosis in cancer cell lines. The inventors contemplate that the active compounds and structurally related species may be used to treat, prevent or ameliorate cancers, particularly cancers that are characterized to be resistant to apoptosis. For example, expression of apoptosis regulatory proteins is aberrant in carcinomas of the breast, colon, lung, bladder, ovary and vulva, sarcomas, lymphomas (AML, NHL), and Li-Fraumeni syndrome.
Advantageously, it is expected that the active compounds can be used as anti-cancer agents. It is contemplated that cancers which may be treated include
36
solid tumors and leukemias (for example B cell, mixed cell, null cell, T cell, T-cell chronic, HTLV-II-associated, lymphocytic acute, lymphocytic chronic, mast cell, and myeloid leukemias), melanoma, fibrosarcoma, 5 osteosarcoma, neuroblastoma, neurofibroma, sarcoma (for example Ewing, experimental, Kaposi, and mast cell sarcomas) . The cancer may be one of the bone, breast, digestive system, colorectal, liver, pancreatic, pituitary, testicular, central nervous system, lung, 10 urogenital system or prostate. The tumor may be benign or malignant, typically it will be malignant. The tumor may be a primary or secondary tumor and may be metastatic.
The active compounds when administered as anticancer agents in medicament form may be administered on 15 their own or in combination with other anti-cancer treatments such as in conjunction with chemotherapy or radiotherapy.
(d) Pharmaceutical Compositions
2 0
The active compounds for use as a cell antiproliferative or apoptotic agent may be administered in pure form or in an appropriate pharmaceutical composition. In general, suitable pharmaceutical 25 compositions may be prepared according to methods which are known to those of ordinary skill in the art. The compositions comprising the active compounds disclosed herein may include a conventional pharmaceutical carrier or diluent, and in addition, may include other medicinal 30 agents, pharmaceutical agents, carriers, adjuvants, etc.
Examples of suitable pharmaceutical carriers or diluents
37
include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Other suitable pharmaceutical carriers are described in Remington's 5 Pharmaceutical Sciences (Mack Publishing Company), a standard reference text in this field, or in U.S. Pharmacopeia National Formulary, 1857-1853, (1990). Typically, the carrier(s) or diluent(s) will form from about 10% to about 99.9% by weight of the compositions. 10 Administration of the active compounds disclosed herein, in pure form or in an appropriate pharmaceutical composition, may be carried out via any of the acceptable modes of administration or pharmaceutically acceptable means of delivery. The modes of administration and 15 pharmaceutically acceptable means of delivery may include oral administration or delivery in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms. The dosage forms may include tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, 20 solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
Oral administration of the disclosed active compounds may be effected by preparing a mixture of the 25 disclosed active compounds with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsules, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet. For oral therapeutic 30 administration, the disclosed active compounds may be incorporated with excipients and used in the form of
38
ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations may contain the active compounds in an amount by weight per volume percent 5 selected from the group consisting of about 0.005% to about 50%, about 0.01% to about 50%, about 0.02% to about 50%, about 0.05% to about 50%, about 0.1% to about 50%, about 0.2% to about 50%, about 0.5% to about 50%, about 1% to about 50%, about 5% to about 50%, about 10% to 10 about 50%, about 15% to about 50%, about 20% to about 50%, about 25% to about 50%, about 30% to about 50%, about 35% to about 50%, about 40% to about 50%, about 45% to about 50%, about 0.005% to about 45%, about 0.005% to about 40%, about 0.005% to about 35%, about 0.005% to 15 about 30%, about 0.005% to about 25%, about 0.005% to about 20%, about 0.005% to about 15%, about 0.005% to about 10%, about 0.005% to about 5%, about 0.005% to about 1%, about 0.005% to about 0.5%, about 0.005% to about 0.2%, about 0.005% to about 0.1%, about 0.005% to 20 about 0.05%, about 0.005% to about 0.02%, and about 0.005% to about 0.01%. Preferably, the active compounds are present in an amount, by weight per volume percent selected from the group consisting of about 0.02% to about 40%, about 0.02% to about 30%, about 0.02% to about 25 20%, about 0.02% to about 15%, about 0.02% to about 14%, about 0.02% to about 13%, about 0.02% to about 12%, about 0.02% to about 11%, about 0.02% to about 10%, and about 0.02% to about 9%. Preferably, the active compounds are present in an amount by weight per volume percent 30 selected from the group consisting of about 0.2% to about 10%, about 0.2% to about 9%, about 0.2% to about 8%,
39
about 0.2% to about 7%, about 0.2% to about 6%, about 0.2% to about 5%, about 0.2% to about 4%, about 0.2% to about 3%, about 0.2% to about 2%, about 0.2% to about 1%, about 0.2% to about 0.9%, about 0.2% to about 0.8%, about 5 0.2% to about 0.7%, about 0.2% to about 0.6%, about 0.2% to about 0.5%, about 0.2% to about 0.4%, and about 0.2% to about 0.3%. In one embodiment, the active compounds are present in an amount by weight per volume percent of about 0.2% to about 1%.
10 The tablets, troches, pills, capsules and the like may also contain the following: a binder, such as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; 15 a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the dosage unit form is a capsule, it may contain, in addition to 20 materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup of elixir may 25 contain sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavorings, such as cherry or orange flavor. Any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. 30 In addition, the active compounds may be incorporated into sustained-release preparation and formulations.
40
The active compounds disclosed herein may be administered parenterally or intraperitoneally. Solutions of the disclosed active compounds as free base or pharmacologically acceptable salts may be prepared in 5 water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to 10 prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use may include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all 15 cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier 20 may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity may be maintained, for example, by the 25 use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms may be brought about by various antibacterial and antifungal agents, for example, 30 parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. Prolonged absorption of the injectable
41
compositions can also be brought about by including in the composition an agent which delays absorption, for example, aluminium monostearate and gelatin.
Preferably, the pharmaceutical form may further 5 include a suitable buffer to minimise acid hydrolysis. Suitable buffer agents are well known to those skilled in the art and include, but are not limited to, phosphates, citrates, carbonates and mixtures thereof.
The active compounds may also be administered in the 10 form of a "prodrug". A prodrug is an inactive form of a compound which is transformed in vivo to the active form. Suitable prodrugs include esters, phosphonate esters etc, of the active form of the compound.
The active compounds in pharmaceutically acceptable 15 form may be administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compounds employed; the metabolic stability and length of action of the compounds; the age, body weight, general health, sex 20 and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disease states; and the patient undergoing treatment.
Single or multiple administrations of the 25 pharmaceutical compositions according to the invention may be carried out. One skilled in the art would be able, by routine experimentation, to determine effective, nontoxic dosage levels of the compound and/or composition of the invention and an administration regime which would be 30 suitable for treating the diseases and/or conditions to which the compounds and compositions are applicable.
42
It will be apparent to one of ordinary skill in the art that the optimal course of treatment, such as the number of doses of the compound or composition of the invention given per day for a defined number of days, can 5 be ascertained using conventional course of treatment determination tests.
Generally, an effective dosage per 24 hours for use of the active compounds as anti-proliferative agents in a pharmaceutical composition may be in the range of about 10 0.5 mg per kg body weight to about 150 mg per kg body weight, about 0.5 mg per kg body weight to about 140 mg per kg body weight, about 0.5 mg per kg body weight to about 130 mg per kg body weight, about 0.5 mg per kg body weight to about 120 mg per kg body weight, about 0.5 mg 15 per kg body weight to about 110 mg per kg body weight, about 0.5 mg per kg body weight to about 100 mg per kg body weight, about 0.5 mg per kg body weight to about 90 mg per kg body weight, about 0.5 mg per kg body weight to about 80 mg per kg body weight, about 0.5 mg per kg body 20 weight to about 70 mg per kg body weight, about 0.5 mg per kg body weight to about 60 mg per kg body weight, about 0.5 mg per kg body weight to about 50 mg per kg body weight, about 0.5 mg per kg body weight to about 40 mg per kg body weight, about 0.5 mg per kg body weight to 25 about 30 mg per kg body weight, about 0.5 mg per kg body weight to about 20 mg per kg body weight, about 0.5 mg per kg body weight to about 10 mg per kg body weight, about 0.5 mg per kg body weight to about 5 mg per kg body weight, about 1 mg per kg body weight to about 150 mg per 30 kg body weight, about 5 mg per kg body weight to about 150 mg per kg body weight, about 10 mg per kg body weight
43
to about 150 mg per kg body weight, about 20 mg per kg body weight to about 150 mg per kg body weight, about 30 mg per kg body weight to about 150 mg per kg body weight, about 40 mg per kg body weight to about 150 mg per kg 5 body weight, about 50 mg per kg body weight to about 150 mg per kg body weight, about 60 mg per kg body weight to about 150 mg per kg body weight, about 70 mg per kg body weight to about 150 mg per kg body weight, about 80 mg per kg body weight to about 150 mg per kg body weight, 10 about 90 mg per kg body weight to about 150 mg per kg body weight, about 100 mg per kg body weight to about 150 mg per kg body weight, about 110 mg per kg body weight to about 150 mg per kg body weight, about 120 mg per kg body weight to about 150 mg per kg body weight, about 130 mg 15 per kg body weight to about 150 mg per kg body weight, or about 140 mg per kg body weight to about 150 mg per kg body weight. Suitably, an effective dosage is in the range of about 1 mg per kg body weight to about 100 mg per kg body weight, about 5 mg per kg body weight to 20 about 100 mg per kg body weight, about 6 mg per kg body weight to about 100 mg per kg body weight, about 7 mg per kg body weight to about 100 mg per kg body weight, about 8 mg per kg body weight to about 100 mg per kg body weight, about 9 mg per kg body weight to about 100 mg per 25 kg body weight, about 10 mg per kg body weight to about 100 mg per kg body weight, about 11 mg per kg body weight to about 100 mg per kg body weight, about 12 mg per kg body weight to about 100 mg per kg body weight, about 13 mg per kg body weight to about 100 mg per kg body weight, 30 about 14 mg per kg body weight to about 100 mg per kg
44
body weight, or about 15 mg per kg body weight to about 100 mg per kg body weight.
The active compounds of general formula (I) may be used in combination with other known treatments or anti-5 proliferative or apoptotic agents. Combinations of active agents, including the active compounds of the invention, may be synergistic.
Noil-therapeutic Uses of Active Compounds
- * ■ ■
10
The active compounds of general formula (I) are capable of inducing apoptosis by inhibiting the functions of pro-survival proteins such as Bcl-xL and Mcl-1. The active compounds may therefore serve as molecular probes 15 to understand the mechanism of cell survival and cell death in research and drug discovery in order to develop novel anti-cancer drugs. It has been found that compounds of the present invention may selectively target and inhibit one of Mcl-1 and Bcl-xL, or inhibit both Mcl-1 20 and Bcl-xL, and may be developed for use as molecular probes in biological assays. Exemplary biological assays include those for studying apoptotic pathways and/or mechanisms, mitochondrial membrane permeability, and mechanisms of tumorigenesis.
25
Examples
Non-limiting embodiments of the disclosed active 30 compounds will be further described in greater detail by reference to specific Examples, which should not be
45
construed as in any way limiting the scope of the invention.
Synthesis of Phenolic Analogues
5
Materials
The chemical reagents and solvents used in the following examples were purchased from Sigma-Aldrich, Alfa Aesar and Merck.
10
Analytical Protocols
(a) Analytical High Performance Liquid Chromatography (HPLC)
15 Analytical HPLC was performed on a Waters HPLC
system equipped with a Waters 2998 PDA detector, Wafers 2695 separation module using a X-Bridge C18 (4.6 mm I.D. x 150 mm, 5jiM) column. A gradient elution starting with 20% CH3CN, 80% (0.1% formic acid/H20) or 30% CH3CN, 70% 20 (0.1% formic acid/H20) , and ending with 100% CH3CN at a flow rate of 1.0 mL/min over 15 min was used.
(b) Preparative HPLC
Preparative HPLC was performed on a Shimadzu LC-8A 25 HPLC system equipped with a CBM-20A PDA detector, Gilson 215 liquid handler and fraction collector using a X-Bridge Prep Ci8 (30 mm I.D. x 50 mm, 5p). column. An isocratic elution with 20% CH3CN, 80% (0.1% formic acid/H20) at a flow rate of 20.0 mL/min for 5 min was 30 used. This was followed by a gradient elution starting
46
with 20% CH3CN, 80% (0.1% formic acid/H20), and ending with 100% CH3CN at a flow rate of 20.0 mL/min.
(c) Liquid Chromatography-Mass Spectrometry (LC-MS)
5 LC-MS data for JC025, JC026, JC028, JC030 and JC041
was collected on a Shimadzu LCMS-IT-TOF instrument equipped with SPD-M20A PDA detector, LCMS-IT-TOF MS detector and LC-20AD binary gradient pump using a Shimpack VP-ODS (2.0 mm I.D. x 150 mm) column. An 10 isocratic elution with 20% H20 and 80% CH3CN at a flow rate of 0.2 mL/min over 3 min was used.
LC-MS data for JC051-JC057 was collected on a Shimadzu Prominence Series LCMS-IT-TOF instrument equipped with SPD-M20A PDA detector, LCMS-IT-TOF MS 15 detector and LC-20AD binary gradient pump using a Shimpack VP-ODS (2.0 mm I.D. x 250 mm) column. Mobile phase is 0.1% formic acid in CH3CN and 0.1% formic acid in H20. A gradient elution was set at 0 min 20% acetonitrile, 13 min 100% acetonitrile, 14 min 100% 20 acetonitrile, 15 min 20% acetonitrile and stop time 16 min.
Example 1: Synthetic Procedure for Analogues
O
H,N-R
2-Hydroxypyridine
an. CH2CI2 or DMF
HO
OH
R
2 mmol) and 2-in anhydrous
25 To a solution of lactone (1
hydroxypyridine (0.1 - 0.2 mmol]
dichloromethane or anhydrous DMF (2-5 mL) was added an amine (1.1 - 2.2 mmol). The mixture was stirred at room
4 7
temperature for 6 to 24 h. After the reaction, water (20 mL) was added. The reaction mixture was transferred to a separating funnel and extracted with dichloromethane, CH2CI2 (3 x 10 mL). The solvent extracts were concentrated 5 under reduced pressure to give a crude product, which was purified by silica gel column chromatography (using hexane/ethyl acetate, 1:1 v/v as eluent) or preparative HPLC (using the protocol set out in "Analytical Protocols" above) to give the final product.
10
Example 2: Analytical Data on Phenolic Analogues
The phenolic analogues prepared in Example 1 above were analyzed using the analytical protocols set out 15 above. The resulting mass spectral, yield and purity data for each analogue are tabulated in Table 1 below.
Table 1. Analytical Data on Phenolic Analogues
Test Sample
Structure
Exact Mass (calculated)
Exact Mass (observed)
Purified Yield (%)
HPLC Purity (%)
JC025
O
n
252.1600 [M+H]+
252 . 1594 [M+H]'
49.4
>99
JC026
0
H0-O
280.1913 [M+H]+
280 .1901 [M+H]+
22 . 0
71
JC028
0
J^OH
259.1077 [M+H]+
259.1077 [M+H]+
37 . 4
>99
48
49
JC057
/=\
311.1396
311.1398
80
92
0 HN--jj
[M+H]+
[M+H] H"
H
A^oh
As can be seen above, the compounds of formula (I) can be prepared in high purity ranging from about 71% up 5 to >99% purity.
Apoptosis Inducing Ability and Cytotoxicity of Phenolic
Analogues
10 In vitro fluorescence polarization (FP)binding assay -Bcl-xL and Mcl-1 Assays
The in vitro florescence polarization binding assays were carried out to identify the inhibitors that block the interaction of Bcl-xL/Bak BH3 domain (Chan, S. et al.
15 (2003) J. Biol. Chem., 278 (23) : 20453-20456; and Zhang, C.
et al. (2002) Anal. Biochem., 307:70-75) and Mcl-l/Bak BH3 domain.
Recombinant GST (glutathio S-transferase) fusion proteins of GST-Bcl-xL and GST-Mcl-1 were expressed in E.
20 coli BL21. The purification of GST fusion proteins was carried out with glutathione sepharose beads and eluted with glutathione elution buffer. Fluorescence labelled peptide of Bak BH3 domain was synthesized by Mimotopes (Australia).
25 FP assay measures the molecular movement and rotation of the fluorescence labelled Bak BH3 peptide (fluo-Bak BH3). In the absence of inhibitors, free rotation of fluo-Bak BH3 is significantly induced due to
50
its binding with Bcl-xL or Mcl-1 proteins. Thus, excitation of fluorescein with polarized light results in a high polarized readout (reading of negative control indicating high polarization). When inhibitor(s) are 5 incubated with Fluo-Bak BH3 and Bcl-xL or Mcl-1 there is competitive binding for Bcl-xL or Mcl-1, and the free rotating Fluo-Bak BH3 results in a low polarized readout (- reading of positive indicating low polarization).
Bcl-xL or Mcl-1 was prepared at a concentration of 10 0.125 pg/iiL with 50 mM Tris buffer (pH 8.0) . Fluo-Bak BH3 was prepared at a concentration of 100 nM with 50 mM Tris buffer (pH 8.0).
The FP assay was conducted on 96-well plate. The procedure of FP assay included adding 10 pL/well testing 15 sample, followed by 30 p.L/well Bcl-xL or Mcl-1 protein, and finally adding 60 pL/well Fluo-Bak BH3. The mixture was incubated at room temperature for 1 hr, after which the fluorescent polarization readout was measured with Tacan Infinite 200 using polarized filter excitation at 20 495 nM and emission at 535 nM.
In vivo Cell Viability Assay
The cell viability assays were conducted with HepG2 25 cell line (human hepatocellular carcinoma, with deposit number ATCC HB-8065) . The assay uses the indicator dye resazurin to measure the metabolic capacity of cells. Viable cells retain the ability to reduce resazurin into resorufin, which is highly fluorescent. Conversely, non-30 viable cells rapidly lose metabolic capacity, and therefore are not able to reduce the indicator dye and generate a fluorescent signal.
51
The assay procedure included adding 100 \iL of 105/mL HepG2 cells into a 96-well plate. The cells were incubated at 37°C overnight, after which 10 pL/well 5 sample was added on the following day. The sample/cell mixture was incubated for 24 hrs at 37°C. This was followed by adding 20 pL/well of 200 pg/mL resazurin. The mixture was incubated at 37°C for 4 hrs. The plate was then read at an excitation wavelength of 535 nm with 10 Tecan Infinite 200.
Example 3: Apoptosis Inducing and Cytotoxic Properties of Phenolic Compounds
15 Table 2. Apoptosis Inducing and Cytotoxicity Properties of Phenolic Compounds
Test Sample
Structure
Bcl-xL IC50 <pM)
Mcl-1 IC50 <HM)
HepG2 IC 50 (pM)
Gossypol
°Yh ohvyy™
H°Y|XSl|^OH
HO-V1^ °Hh^O
46
49
117
JC025
0
A™
HO"^
133
138
569
JC026
0
1 H
ifS"0H
hcA^
101
84
522
52
JC02 8
116
136
478
JC030
/"Xr)
^OH 0
JJ
■ 97
98
354
JC041
O
ZI X
/ O
\
o
X
94
95
282
JC051
0
if no' ;
>830
145
>830
JC052
0
f H
^v-0H
HO^
>650
87 ,
>650
JC053
o
J^OH
JJ
91
110
336
JC054
XrXf
H
Xks/0H HO-U
86
81
324
JC055
XoO
H
J^OH
HO-XJ
98
125
417
JC05 6
rAB'Yl
/L-OH ^^och3 HO^U
122
134
348
53
It can be seen from Table 2 above that phenolic analogues JC025, JC026, JC028, JC030, JC041 and JC053-057 have significant inhibitory effects on both pro-survival 5 proteins Bcl-xL and Mcl-1. Compounds JC051 and JC052 exhibit selective inhibitory effect on Mcl-1, which is of particular interest in cancer therapy.
The compounds also exhibited, low cytotoxic effects on the human cancer cell line HepG2. Compounds JC051 and
10 JC052, in particular, have very low cytotoxicity.
When compared to a known Bcl-xL inhibitor, Gossypol, it can be seen that the phenolic compounds JC025, JC026, JC028, JC030, JC041 and JC051-057 have significantly lower cytotoxicity than Gossypol.
15
Comparative Example
Table 3. Comparison of Different Phenolic Analogues in Inhibiting Pro-survival Proteins Bcl-xL and/or Mcl-1
20
Test Sample
Structure
Bcl-xL 1C50 (pM)
Mcl-1 IC50 (|*M)
JC025
0
II
133
138
(Present
Invention)
X H
fVOH
JC025' (Compara tive Sample)
>840
>840
54
JCC26 (Present Invention)
Jr
101
84
JC02 6' (Comparative Sample)
N
>400
>400
JC028 (Present Invention)
rtfo
116
136
JC028' (Comparative Sample)
rVo
A^oh ^
U
>820
>820
J CO 30 (Present Invention)
JT
97
98
JC030' (Comparative Sample)
>700
>7 00
The comparative data in Table 3 demonstrate that the presence of a hydroxyl moiety at carbon-2 and carbon-5 positions of the phenyl group of the compounds of formula 5 (I) is advantageous for inhibiting the Bcl-xL and Mcl-1 proteins. For example, JC025, JC028 and JC030 exhibit significantly more potent inhibitory activity on both pro-survival proteins than JC025', JC028' and JC030', respectively, which have only one hydroxyl group on the 10 phenyl ring.
By comparing JC026 and JC026' , it can also be seen that the absence of a hydroxyl, alkoxy, thiol or thioether group on the phenyl ring also compromises the
55
inhibitory activity of the compounds on both pro-survival proteins.
In summary, phenolic analogues JC025, JC026, JC028, JC030, JC041 and JC053 to JC057 show inhibitory effects 5 towards both Bcl-xL and Mcl-1 pro-survival proteins and have low cytotoxicity toward HepG2 cell line, while phenolic analogues JC051 and JC052 show selective inhibition towards Mcl-1 protein and also have low cytotoxicity toward HepG2 cell line. 10 Advantageously, as the phenolic analogues target the
Bcl-xL and Mcl-1 pro-survival proteins, which are often over-expressed in cancer and tumor cells, the phenolic analogues can selectively target and cause apoptosis of these cells without causing any anti-proliferative or 15 apoptotic effect on normal (i.e. non-tumor and noncancerous) cells.
Applications
20 The active compounds disclosed herein have demonstrated strong pro-survival protein inhibitory and cell apoptotic activities.
Advantageously, the disclosed active compounds may be used as apoptotic/anti-proliferative agents in the 25 manufacture of medicaments for treatment of conditions in which cells proliferate abnormally and/or show resistance to apoptosis.
Exemplary proliferative conditions include, but are not limited to, pre-malignant and malignant cellular 30 proliferation, such as malignant neoplasms, tumours (e.g. solid tumours), cancers, leukemia and infections (e.g.
56
fungal infection, bacterial infection etc.), and the like.
The surprising selective inhibition of Mcl-1 protein by phenolic analogues JC051 and JC052 also provide the 5 compounds of the present invention with the ability to be used as a molecular probe in medical research to target a particular pro-survival protein and independently study the mechanism or pathway of inhibition of such a protein.
Further, as discussed hereinabove, Mcl-1 has emerged 10 as a major resistance factor in human cancer. Inhibition of Mcl-1 by small organic molecules, such as the active phenolic analogues of the present invention, will prove to be a valuable strategy in circumventing the chemoresistance of cancer cells. Therefore, the active 15 compounds of the present invention may be used in the manufacture of a medicament for the prevention and/or treatment of a condition associated with resistance to anti-cancer drugs.
57
Claims (1)
- Claims1. Use of a compound represented by the general formula5 (I) :and pharmaceutically acceptable salts thereof, wherein n is an integer from 2 to 5;10 p is an integer from 0 to 4;Ri is independently selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group, wherein at least two of Ri are on the carbon-2 and carbon-5 positions of the phenyl 15 group;R2 and R3 are independently a methylene group or a nucleophile;Z is an oxygen (0) atom or sulfur (S) atom; and T is hydrogen or an optionally substituted aliphatic 20 group or optionally substituted aryl group;in the manufacture of a medicament for prevention and/or treatment and/or containment of a condition associated with a cell proliferative disorder.25 2. The use as claimed in claim 1, wherein n is 2.583. The use as claimed in claim 1 or 2, wherein Ri is hydroxyl.4. The use as claimed in anyone of the preceding 5 claims, wherein p is 0.5. The use as claimed in any one of the preceding claims, wherein Z is an oxygen (0) atom.10 6. The use as claimed in any of claims 1-5, wherein Tis an aliphatic group with 1 to 8 carbon atoms.7. The use as claimed in any of claims 1-5, wherein Tis an aliphatic group with at least 9 carbon atoms.158 . The use as claimed in any one of the preceding claims, wherein T is an alkyl.9. The use as claimed in claim 8, wherein the alkyl of20 T is straight or branched chain.10. The use as claimed in any one of the preceding claims, wherein the aliphatic group of T is an aliphatic group containing at least one unsaturated25 alkenyl or alkynyl group.11. The use as claimed in any one of the preceding claims, wherein T is an aliphatic group substituted with heteroatom groups.3059The use as claimed in any one of claims 1 to 5, wherein T comprises an optionally substituted aryl group, heteroaryl group, or cycloalkyl group.The use as claimed in any one of the preceding claims, wherein the nucleophile of R2 and/or R3 is selected from the group consisting of a halide, a nitrogen nucleophile, a sulfur nucleophile and an oxygen nucleophile.The use as claimed in claim 13, wherein the nitrogen nucleophile is an amino group.The use as claimed in claim 14, wherein the amino group is selected from the group consisting of NH, NHV, NVV where V and V' are each independently selected from the group consisting of a C]-C6 lower alkyl, a phenyl, and an alkoxy group.The use as claimed in one of the preceding claims, wherein the compound is selected from the group consisting of:OHOO0■ HON HOH60; and5 17. The use as claimed in any one of the preceding claims, wherein the condition associated with a cell proliferative disorder is selected from the group consisting of tumorigenesis and cancer.10 18.15The use as claimed in claim 17, wherein said cancer is selected from the group consisting of solid tumors, B cell leukemia, mixed cell leukemia, null cell leukemia, T cell leukemia, T-cell chronic leukemia, HTLV-II- associated leukemia, lymphocytic acute leukemia, lymphocytic chronic leukemia, mast cell leukemia, myeloid leukemia, melanoma,61fibrosarcoma, osteosarcoma, neuroblastoma,neurofibroma, Ewing sarcoma, experimental sarcoma, Kaposi sarcoma, mast cell sarcoma, bone cancer, breast cancer, cancer of the digestive system, 5 colorectal cancer, liver cancer, pancreatic cancer,pituitary cancer, testicular cancer, cancer of the central nervous system, lung cancer, cancer of the urogenital system, and prostate cancer.10 19. The use as claimed in any one of the preceding claims, wherein the treatment of the condition associated with a cell proliferative disorder requires apoptosis of cells with abnormal proliferation and/or resistance to apoptosis.1520. The use as claimed in claim 19, wherein the apoptosis occurs by inhibition of a pro-survival protein.20 21. The use as claimed in claim 20, wherein the pro-survival protein is selected from the group consisting of: Bcl-xL and Mcl-1.22. The use as claimed in claim 21, wherein the25 apoptosis occurs by inhibition of Mcl-1.23. The use according to any one of claims 1 to 15, wherein the compound is selected from the group consisting of:30624. The use according to claim 23, wherein the treatment of the condition associated with a cell proliferative disorder requires suppression of Mcl-1.5. Use of a compound represented by the general formula (I) :and pharmaceutically acceptable salts thereof, wherein n is an integer from 2 to 5;p is an integer from 0 to 4;Ri is independently selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group, wherein at least two of Ri are on the carbon-2 and carbon-5 positions of the phenyl group;R2 and R3 are independently a methylene group or a nucleophile;Z is an oxygen (0) atom or sulfur (S) atom; and63T is hydrogen or an optionally substituted aliphatic group or optionally substituted aryl group;in the manufacture of a molecular probe.5 26. The use as claimed in claim 25, wherein n is 2.27. The use as claimed in claim 25 or 26, wherein Ri is hydroxyl.10 28. The use as claimed in any one of claims 25 to 27,wherein p is 0.29. The use as claimed in any one of claims 25 to 28, wherein Z is an oxygen (0) atom.1530. The use as claimed in any one of claims 25 to 29, wherein T is an aliphatic group with 1 to 8 carbon atoms.20 31. The use as claimed in any one of claims 25 to 30,wherein T is an aliphatic group with at least 9 carbon atoms.32. The use as claimed in any one claims 25 to 30,25 wherein T is an alkyl.33. The use as claimed in claim 32, wherein the alkyl of T is straight or branched chain.30 34. The use as claimed in any one of claims 25 to 31,wherein the aliphatic group of T is an aliphatic64group containing at least one unsaturated alkenyl or alkynyl group.The use as claimed in any one of claims 25 to 34, wherein T is an aliphatic group, substituted with heteroatom groups.The use as claimed in any one of claims 25 to 29, wherein T comprises an optionally substituted aryl group, heteroaryl group, or cycloalkyl group.The use as claimed in any one of claims 25 to 36, wherein the nucleophile of R2 and/or R3 is selected from the group consisting of a halide, a nitrogen nucleophile, a sulfur nucleophile and an oxygen nucleophile.The use as claimed in claim 37, wherein the nitrogen nucleophile is an amino group.The use as claimed in claim 38, wherein the amino group is selected from the group consisting of NH, NHV, NVV' where V and V' are each independently selected from the group consisting of a Ci-C6 lower alkyl, a phenyl, and an alkoxy group.Use of a compound represented by the general formula (I) :65and pharmaceutically acceptable salts thereof, wherein n is an integer from 2 to 5;p is an integer from 0 to 4;5 Ri is selected from the group consisting of a hydroxyl group, an alkoxv group, a thiol group, and a thioether group, wherein at least two of Ri are on the carbon-2 and carbon-5 positions of the phenyl group;R2 and R3 are independently a methylene group or a 10 nucleophile;Z is an oxygen (0) atom or a sulfur (S) atom; and T is an optionally substituted aliphatic group having at least 9 carbon (C) atoms;in the manufacture of a medicament for the 15 prevention and/or treatment of a condition associated with resistance to anti-cancer drugs.41. The use as claimed in claim 40, wherein n is 2.20 42. The use as claimed in any one of claims 40 or 41,wherein p is 0.43. The use as claimed in any one of claims 40 to 42,wherein the nucleophile of R3 is selected from the 25 group consisting of a halide, a nitrogen66nucleophile, a sulfur nucleophile and an oxygen nucleophile.44. The use as claimed in claim 43, wherein the nitrogen 5 nucleophile is an amino group.45. The use as claimed in claim 44, wherein the amino group is selected from the group consisting of NH, NHV, NVVf where V and V' are each independently10 selected from the group consisting of a C1-C6 lower alkyl, a phenyl, and an alkoxy group.46. The use as claimed in any one of claims 40 to 45, wherein T is an aliphatic group with 9 carbon atoms.1547. The use as claimed in any one of claims 40 to 46,0wherein the compound is H°48. The use as claimed in any one of claims 40 to 45, 20 wherein T is an aliphatic group with 10 carbon (C)atoms.49. The use as claimed in claim 48, wherein the compound o256750.551.; lo52.1553.The use as claimed in any one of claims 40 to 49, wherein the condition associated with resistance to anti-cancer drugs is resistance to an anti-cancer drug selected from the group consisting of ABT-737, GX15-070, ABT-263 and AT-101.The use as claimed in any one of claims 40 to 50, wherein the condition associated with resistance to anti-cancer drugs is a high level of Mcl-1 expression.The use as claimed in any one of claims 40 to 51, wherein the medicament for the prevention and/or treatment of a condition associated with resistance to anti-cancer drugs selectively inhibits Mcl-1.A compound selected from the group consisting of:O0o oo o206854. A method of inducing apoptosis in a patient in need5 thereof comprising administering an effective amount of a compound represented by the general formula (I) :n(Ri) (I)10 and pharmaceutically acceptable salts thereof, wherein n is an integer from 2 to 5;p is an integer from 0 to 4;Ri is independently selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol 15 group, and a thioether group, wherein at least two of Ri are on the carbon-2 and carbon-5 positions of the phenyl group;69R2 and R3 are independently a methylene group or a nucleophile;Z is an oxygen (0) atom or sulfur (S) atom; and T is hydrogen or an optionally substituted aliphatic 5 group or optionally substituted aryl group.55. The method of claim 54, wherein the compound is selected from the group consisting of:157056. The method of claim 54 or 55, wherein the patient in need thereof is a patient with a condition associated with a cell proliferative disorder.1057. The method of claim 56, wherein the condition is cancer.58. The method of claim 56, wherein the condition is tumorigenesis.59. A method of increasing sensitivity to chemotherapy15 in a patient in need thereof comprising-i-administering an effective amount of an Mcl-1 inhibitor selected from a compound represented by the general formula (I):71and pharmaceutically acceptable salts thereof, wherein • n is an integer from 2 to 5;p is an integer from 0 to 4;5 Ri is selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, and a thioether group, wherein at least two of Ri are on the carbon-2 and carbon-5 positions of the phenyl group;R2 and R3 are independently a methylene group or a 10 nucleophile;Z is an oxygen (O) atom or sulfur atom; and T is an optionally substituted aliphatic group having at least 9 carbon (C) atoms.15 60. The method of claim 59, wherein the compound is selected from the group consisting of:61. The method of claim 59 or 60, wherein the patient in20 need thereof is a patient with a condition associated with a cell proliferative disorder.62. The method of claim 61, wherein the condition is cancer.63. The method of claim 61, wherein the condition is 5 tumorigenesis.73
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1203350.2A GB2499666A (en) | 2012-02-27 | 2012-02-27 | Mcl-1 inhibitors for the treatment of conditions associated with proliferative disorders |
PCT/SG2013/000066 WO2013130013A1 (en) | 2012-02-27 | 2013-02-19 | Novel compounds and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1203350.2A GB2499666A (en) | 2012-02-27 | 2012-02-27 | Mcl-1 inhibitors for the treatment of conditions associated with proliferative disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
GB201203350D0 GB201203350D0 (en) | 2012-04-11 |
GB2499666A true GB2499666A (en) | 2013-08-28 |
Family
ID=45991776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1203350.2A Withdrawn GB2499666A (en) | 2012-02-27 | 2012-02-27 | Mcl-1 inhibitors for the treatment of conditions associated with proliferative disorders |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2499666A (en) |
WO (1) | WO2013130013A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010124648A1 (en) * | 2009-04-29 | 2010-11-04 | Industrial Technology Research Institute | Azaazulene compounds |
WO2010144055A1 (en) * | 2009-06-08 | 2010-12-16 | Nanyang Polytechnic | Novel compounds and uses thereof |
WO2010144059A2 (en) * | 2009-06-12 | 2010-12-16 | Nanyang Polytechnic | Novel uses |
WO2011098610A1 (en) * | 2010-02-12 | 2011-08-18 | Universita Degli Studi Di Firenze | Carbonic anhydrase inhibitors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2231465A1 (en) * | 1995-09-07 | 1997-03-13 | Kissei Pharmaceutical Co., Ltd. | 2-acylaminobenzamide derivatives and an agent for the prevention and treatment of diseases caused by excessive proliferation of vascular intimal cells |
WO2006033795A2 (en) * | 2004-09-17 | 2006-03-30 | Wyeth | Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth |
CA2608726C (en) * | 2005-05-20 | 2013-07-09 | Methylgene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
WO2008060789A2 (en) * | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
AU2009305565A1 (en) * | 2008-10-17 | 2010-04-22 | Exelixis, Inc. | Synergistic combination of sphingosine-1-phosphate receptor antagonists and antimicrotubule agents |
KR101714799B1 (en) * | 2008-12-30 | 2017-03-09 | 아르퀼 인코포레이티드 | Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds |
WO2010138421A1 (en) * | 2009-05-27 | 2010-12-02 | Merck Sharp & Dohme Corp. | HEXAHYDROCYCLOPENTYL[f]INDAZOLE REVERSED AMIDES AND DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
EP2609072A4 (en) * | 2010-08-27 | 2014-03-19 | Univ Singapore | Chalcone structure fluorescence dye for embryonic stem cell probe |
-
2012
- 2012-02-27 GB GB1203350.2A patent/GB2499666A/en not_active Withdrawn
-
2013
- 2013-02-19 WO PCT/SG2013/000066 patent/WO2013130013A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010124648A1 (en) * | 2009-04-29 | 2010-11-04 | Industrial Technology Research Institute | Azaazulene compounds |
WO2010144055A1 (en) * | 2009-06-08 | 2010-12-16 | Nanyang Polytechnic | Novel compounds and uses thereof |
WO2010144059A2 (en) * | 2009-06-12 | 2010-12-16 | Nanyang Polytechnic | Novel uses |
WO2011098610A1 (en) * | 2010-02-12 | 2011-08-18 | Universita Degli Studi Di Firenze | Carbonic anhydrase inhibitors |
Non-Patent Citations (2)
Title |
---|
Journal of Medicinal Chemistry, Vol.54(24), 2011, Cherkasov, pages 8563-8573. * |
Tetrahedron Letters Vol.52, 1975, Krohn, pages 4667-8. * |
Also Published As
Publication number | Publication date |
---|---|
WO2013130013A1 (en) | 2013-09-06 |
GB201203350D0 (en) | 2012-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021120420A (en) | Methods of treating cancer | |
CA2870005C (en) | Salt form of a human histone methyltransf erase ezh2 inhibitor | |
CN103086935B (en) | Diphenyl selenide, diphenyl selenoxide, diphenyl selenone compounds and uses thereof | |
KR20190128673A (en) | Pyrimidopyrimidinone Useful as Wee-1 Kinase Inhibitor | |
CN111253336A (en) | Compounds for the treatment of cancer | |
WO2017117070A1 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
US10561681B2 (en) | Antimetastatic 2H-selenopheno[3,2-h]chromenes, synthesis thereof, and methods of using same agents | |
AU2021376500A1 (en) | Application of isoquinoline compound in tumor treatment | |
CA2940694A1 (en) | Disubstituted triazole analogs | |
KR101975299B1 (en) | Compounds containing core structure of indole acetic acid and uses thereof | |
CA2892584A1 (en) | New inhibitors of the sodium iodide symporter | |
WO2023244946A1 (en) | Prodrugs of stat3 inhibitors | |
GB2499666A (en) | Mcl-1 inhibitors for the treatment of conditions associated with proliferative disorders | |
KR20190043842A (en) | Pyrimidine-2-amine derivative, a method for producing the same, and an anticancer drug containing the same | |
CN117321064A (en) | Gemcitabine anticancer derivative and anticancer medical application thereof | |
WO2017066558A1 (en) | Nicotinic acetylcholine receptor silent agonists | |
US20220110962A1 (en) | Analogues of oleuropein and oleacein and uses thereof | |
Soni | DEVELOPMENT OF SALINOMYCIN DERIVATIVES AS POTENTIAL ANTICANCER AGENTS | |
CN118027003A (en) | PROTAC compound, preparation method thereof and application of PROTAC compound as estrogen receptor degradation agent | |
WO2022187403A1 (en) | Thyroid hormone receptor beta agonist compounds | |
CA3140417A1 (en) | Substituted fluorine-containing imidazole salt compound, preparation method therefor, pharmaceutical composition thereof and use thereof | |
EP4053116A1 (en) | Tricyclic compound and pharmaceutical use thereof | |
KR20210155806A (en) | Polymorphism of PI3K inhibitor and method for preparing same | |
CN116102545A (en) | Diaryl urea PI3K/mTOR/HDAC multi-target inhibitor, and pharmaceutical composition and application thereof | |
UA142117U (en) | 4- [3- (5-Bromo-2-hydroxyphenyl) -5-phenyl-3,4-dihydropyrazol-2-yl] -5H-thiazol-2-one having antitumor activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |